Neurocrine biosciences announces publication of primary cahtalyst™ pediatric phase 3 study results of crinecerfont for the treatment of cah in the new england journal of medicine

-          cahtalyst™ pediatric study met primary and key secondary endpoints, with crinecerfont treatment decreasing androstenedione levels and enabling glucocorticoid dose reduction while maintaining androstenedione control     -          30% of crinecerfont participants achieved a physiologic glucocorticoid dose at week 28 while maintaining androgen control versus 0% of placebo participants     -          favorable trends in endpoints reflecting supraphysiologic glucocorticoid dosing and androgen excess     -          crinecerfont was generally well tolerated san diego , june 3, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that the primary study results from its cahtalyst™ pediatric phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency have been published in the new england journal of medicine online edition and will appear in a future print issue of the journal. the cahtalyst pediatric phase 3 study met the primary and key secondary endpoints related to androgen reduction (during an initial glucocorticoid-stable period) and glucocorticoid (gc) dose reduction while maintaining androgen control.
NBIX Ratings Summary
NBIX Quant Ranking